a2 Milk Cuts FY26 Outlook as China Supply Crunch Pushes Sales Into Next Year

a2 Milk downgrades FY26 guidance as China supply chain disruption hits availability

The a2 Milk Company (ASX: A2M) has revised its FY26 financial guidance downward following temporary supply chain constraints that have materially affected China label infant milk formula (IMF) availability. The company now expects revenue growth of low to mid double-digit percent versus FY25’s $1,757 million, down from prior guidance of mid double-digit growth, with EBITDA margin compressed to 14.0%-14.5% from 15.5%-16.0%. Management has emphasised the disruption is primarily a timing issue rather than a structural demand problem, with underlying demand remaining strong across all product categories and regions throughout Q3 FY26.

The revised outlook reflects a confluence of external factors affecting product flows to Chinese distributors and retailers during Q4 FY26, particularly in April and May 2026. EBITDA margin compression stems from additional one-off supply chain costs and lower sales volumes, partially offset by cost saving initiatives. Cash conversion has been downgraded to approximately 50% from 80% as revenue timing shifts into FY27, whilst net profit after tax (NPAT) is now expected to be similar to down on FY25’s reported $203 million, previously guided to increase.

Despite the near-term headwinds, the company has confirmed it will continue reinvesting in brand health and growth initiatives during Q4 FY26 to support long-term value creation.

Five factors converging to constrain China IMF supply

The supply chain is experiencing a convergence of temporary disruptions affecting product availability at distributor and retailer level. These factors have evolved rapidly and remain subject to uncertainty, particularly regarding freight and customs clearance timing.

The five primary constraints are:

1. Strong demand partially supported by international competitor product recalls — Elevated demand for a2™ IMF imported products has strained available inventory, with some uptick linked to competitor recalls in the international market creating switching opportunities.

2. Freight constraints linked to Middle East conflict affecting capacity allocations — The availability and cost of additional air freight required to accelerate product shipments to China has been indirectly impacted by geopolitical instability, with variability in capacity allocations for sea freight.

3. Low inventory levels due to past Synlait manufacturing challenges; production now at target but backlog remains — a2 Milk inventory levels have been low throughout FY26 due to historical Synlait manufacturing challenges and other operational issues. While production at Synlait has recently returned to target levels, a significant backlog of unfilled purchase orders remains, with less capacity to recover following Synlait’s sale of its North Island assets.

4. Extended quality assurance release times from enhanced cereulide testing standards — Emerging industry standards relevant to ingredient suppliers and IMF manufacturers require enhanced cereulide testing measures, extending quality assurance release times and impacting product availability across the sector.

5. Additional customs clearance requirements and higher inspection rates extending release times — Additional clearance requirements and testing measures, including higher inspection and sampling rates for the industry, are extending customs release times and further constraining product availability.

The cumulative effect of these factors is challenging to mitigate given proximity to year end and end-to-end supply chain lead times. The company is urgently working with supply chain and distribution partners in New Zealand and China to expedite product flows.

China label versus English label exposure

China label IMF is the primary affected product line, with material availability shortfalls expected at distributors and retailers mainly during April and May 2026. The impact on this segment is driving the majority of the revised guidance.

English label IMF product faces some exposure to the factors outlined above, particularly additional clearance requirements, but is not expected to be as significantly impacted during this period. However, a2 Genesis™, which represents approximately 6% of cross-border e-commerce (CBEC) sales, is experiencing near-term product availability issues in CBEC channels due to high demand. This constraint will be addressed shortly with resumption of production at a2 Pōkeno following completion of planned canning line capital works and maintenance.

What is cereulide testing and why is it extending release times?

Cereulide is a toxin produced by certain strains of Bacillus cereus bacteria, which can contaminate food products including dairy and infant formula. Exposure to cereulide can cause food poisoning, making its detection critical for food safety standards.

Emerging regulatory standards now require enhanced testing for cereulide before infant milk formula can be released to market. This involves more rigorous laboratory analysis at both the ingredient supplier and finished product manufacturer level, extending the time between production completion and product clearance for distribution.

The enhanced testing protocols are an industry-wide development affecting all IMF manufacturers and ingredient suppliers, not specific to a2 Milk. While these measures create short-term friction in supply chains, higher safety standards can reinforce the quality credentials of premium brands positioned on product integrity and consumer trust.

Demand trends remain strong despite availability constraints

The company reported strong demand for the a2™ brand across all product categories and regions in Q3 FY26, with positive year-to-date offtake trends similar to or better than those experienced in H1 FY26. The underlying demand story remains intact across both China label and English label products.

Key demand highlights include:

• China label a2 至初™ IMF demand remains strong, with early stage new user recruitment continuing to improve after supply constraints in Q1 FY26, supported by the successful My Little Pony marketing campaign

• Later stage growth benefiting from prior period share gains and stage transition, as well as success of the company’s new kids nutrition product

• English label IMF demand continued to be strong, supported by growth in a2 Platinum™ and a2 Genesis™ products across all stages

• Particularly strong performance in the CBEC channel for English label products

The distinction between a supply timing problem and a demand problem is crucial for investors assessing medium-term outlook. The company’s challenge is operational execution to meet existing demand, not demand creation.

Revised FY26 financial outlook

The company has updated its FY26 guidance to reflect the cumulative impact of supply chain constraints, with material changes across revenue growth, profitability, and cash conversion metrics.

Depreciation and amortisation is now expected to be approximately $20 million, revised down from $20-$24 million previously. Interest income is expected to be lower due to lower market rates and net transaction cash outflows.

The delay in cash receipts into FY27 stems from the later timing of IMF sales in Q4 FY26, with product availability constraints pushing revenue recognition beyond the June 2026 year end. Capital expenditure guidance remains unchanged at $60-$80 million as the company continues investing in supply chain transformation.

Notwithstanding these short-term challenges, management has confirmed the company intends to continue reinvesting in the business during Q4 FY26 to support brand health, growth, and long-term value creation.

Supply chain transformation and FY27 outlook

The company’s supply chain transformation programme at a2 Pōkeno remains on track despite near-term disruption elsewhere in the network. Capital upgrade works, recruitment and capability building, product trials, and the new China label registration amendment process are all progressing as planned ahead of an expected production ramp-up in H1 FY27.

This in-house manufacturing capacity represents the structural solution to current supply chain vulnerabilities. By bringing production under direct operational control, the company aims to reduce dependence on third-party manufacturing challenges that have contributed to the current inventory backlog. The H1 FY27 production increases at a2 Pōkeno should materially improve supply chain resilience and responsiveness to demand fluctuations.

The transformation programme is a multi-year capital allocation priority designed to support the company’s long-term growth trajectory in China IMF markets, where premiumisation trends and brand loyalty remain favourable for established quality-positioned players.

Key risks to monitor

The company has disclosed a range of risks that could materially impact expected revenue and earnings outcomes:

• Further delays in freight and clearance timing beyond current assumptions
• Trading upside and downside variability as supply constraints evolve
• Challenging macroeconomic conditions
• China IMF category dynamics and competitive intensity
• Product and supply related risks
• Cross border trade
• Foreign exchange movements
• Changes in interest rates
• Farmgate milk pricing and other commodity prices
• Regulatory changes
• Middle East conflict escalation further constraining logistics capacity

The company has committed to keeping the market informed in accordance with continuous disclosure obligations as these factors develop.

Don’t Miss the Next Consumer Staples Breakout

Join 20,000+ investors getting FREE breaking ASX news and in-depth analysis delivered within minutes of release. Click the “Free Alerts” button at Big News Blast to receive real-time alerts the moment market-moving announcements hit—complete with expert coverage across Healthcare, Tech, Finance, and Consumer sectors.